Go Pro
OTCMKTS:EKTAY

Elekta Q4 2025 Earnings Report

Elekta logo
$5.57 0.00 (0.00%)
As of 08/17/2026 03:28 PM Eastern

Elekta EPS Results

Actual EPS
$0.11
Consensus EPS
$0.13
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$503.22 million
Expected Revenue
$507.19 million
Beat/Miss
Missed by -$3.97 million
YoY Revenue Growth
N/A

Elekta Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Thursday, August 27, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Earnings Headlines

Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume - Still a Buy?
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.tc pixel
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment. Elekta also provides oncology information systems and treatment planning software that enable seamless integration of imaging, planning and delivery for multidisciplinary clinical teams. In addition, the company offers comprehensive service and support programs, clinical training and educational resources to ensure optimal system performance and professional development for its customers.

Founded in 1972 by Swedish neurosurgeon Lars Leksell, Elekta pioneered stereotactic radiosurgery and has since grown into a worldwide provider of precision cancer care technologies. Headquartered in Stockholm, Sweden, the company serves hospitals, cancer centers and clinics across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa. Elekta maintains regional offices and service centers to support installation, maintenance and training programs in key markets around the globe.

Guided by a leadership team of experienced executives and a board of directors with deep expertise in healthcare technology, Elekta continues to invest in research and development to advance treatment efficacy and patient quality of life. The company collaborates with academic institutions, clinical partners and industry stakeholders to drive innovation in radiotherapy and radiosurgery and to shape the future of precision cancer care.

View Elekta Profile